Fosamax Osteonecrosis of the Jaw Settlement: Understanding California's Statute of Limitations

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Assessment

For decades, general health and science communication has served as the foundation for public understanding of medical risks and therapeutic benefits. This legacy context emphasized broad awareness of disease prevention, treatment options, and the importance of informed patient decision-making. Within this framework, discussions of pharmaceutical interventions naturally included both intended outcomes and potential adverse effects, fostering a balanced perspective on medical progress. As this informational heritage evolved, specific therapeutic agents became subjects of focused scrutiny. Bisphosphonates, a class of drugs widely prescribed for bone density management, exemplify this transition from general health discourse to targeted risk assessment. Among these, Fosamax (alendronate) emerged as a commonly used medication, with its long-term safety profile drawing increasing attention from both clinicians and patients. The shift from general health education to occupational exposure concern becomes particularly relevant when considering the manufacturing and handling environments associated with such pharmaceuticals. Workers in production facilities, distribution centers, and healthcare settings may encounter these compounds through inhalation, dermal contact, or inadvertent ingestion during routine operations. This occupational dimension introduces distinct exposure patterns that differ from prescribed therapeutic use, warranting careful consideration of potential health implications. In California, legal frameworks governing product liability and personal injury claims establish specific time limits for seeking compensation. Understanding these statute of limitations requirements is essential for individuals who may have experienced adverse outcomes following Fosamax exposure, whether as patients or through occupational contact.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence

Fosamax (alendronate sodium) is a bisphosphonate medication approved by the U.S. Food and Drug Administration for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Clinical Presentation of ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate that inhibits bone resorption by osteoclasts. This suppression of bone turnover can lead to impaired healing and microdamage accumulation in the jawbone, particularly after dental procedures or infections. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Legal Considerations and California Statute of Limitations

In terms of risk assessment, the adequacy of warnings regarding Fosamax and ONJ is a key consideration. The prescribing information for Fosamax includes a warning under section 5.4 that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms potentially related to ONJ were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that the background incidence of such symptoms in the studied populations was not significantly elevated by Fosamax use, though post-marketing reports have identified ONJ cases. For affected patients in California, settlement-related considerations involve the statute of limitations for filing claims. The timeline between exposure to Fosamax and documented harm is critical, as ONJ can develop months to years after starting the drug, and symptoms may not appear until after a dental procedure. The risk of ONJ may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who have experienced ONJ after using Fosamax should be aware that legal claims must be filed within a certain period after the injury is discovered or should have been discovered. In California, the statute of limitations for personal injury claims is generally two years from the date of injury, but this can vary based on the specifics of the case, including when the harm was reasonably discoverable. Given the delayed onset of ONJ, patients may need to establish when they first became aware of the connection between their jaw condition and Fosamax use. Settlement considerations also include the strength of evidence linking the patient's ONJ to Fosamax, the presence of known risk factors, and the adequacy of warnings provided by the manufacturer. Patients with documented ONJ after Fosamax use, particularly those who underwent dental procedures without being advised to discontinue the drug, may have stronger claims. The clinical presentation of ONJ includes exposed bone in the jaw, often with pain, swelling, and infection, and diagnosis is confirmed by clinical examination and imaging. The multiscale characterization of jawbone can aid in understanding the pathophysiology (https://pubmed.ncbi.nlm.nih.gov/40345077/), but individual cases require careful medical and legal evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury. However, for ONJ, the injury may not be discovered immediately. The clock may start when the plaintiff discovers or reasonably should have discovered the connection between Fosamax and the jaw condition. It is crucial to consult an attorney promptly to avoid missing the deadline.

What are the known risk factors for developing osteonecrosis of the jaw from Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.